2nd Edition of Recombinant Vaccines Produced in Emerging Expression Systems for Human and Animal Health

Dear Colleagues,

The emergence of new pathogens of human and veterinarian interest and the large number of infectious diseases for which there are not vaccines available demands their rapid development. In this scenario, the improvement of the attributes of the vaccine production platforms acquire a special importance to address global vaccination goals. For instance, cost, safety and easy delivery are key aspects defined by the platform select to produce vaccines.  Genetic engineering permits to attenuate viruses, modify viral vectors and bacteria strains to generate recombinant vaccines against infectious diseases. For example, the Modified Vaccina Virus Ankara vaccine has been used as a platform to develop vaccines against Smallpox and SARS-CoV-2. In the veterinary field, the development of live vaccines using nonpathogenic bacteria has become extremely attractive. Most recombinant vaccines require expensive production systems, thus there is a need to accelerate the development of vaccines based on innovative platforms. For example, Nicotiana bethamiana has been used for the production of Influenza antigens. This expression system is more than 10 times less expensive than mammalian cell cultures. Moreover, Lactobacillus and Bacillus sp have been proposed as hosts for the production of low-cost, oral vaccines.  This special issue of Vaccines is intended to bring attention to these innovative systems and to showcase these vaccines so they can move from the bench to clinical trial and finally to the market. The most recent genetic engineering approaches will be emphasized as well as the perspectives for the industrial adoption of such innovative systems for antigen expression and delivery. 

Dr. William C. Wilson
Dr. Mauricio Comas-Garcia
Dr. Sergio Rosales-Mendoza
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• plant-based vaccines
• algae-made vaccines
• Bacillus subtilis-based vaccines
• new expression vectors
• oral vaccines